Shanghai Junshi Biosciences Co., Ltd. (SHJBF)
OTCMKTS · Delayed Price · Currency is USD
3.000
-0.073 (-2.38%)
At close: Jan 6, 2026
Shanghai Junshi Biosciences Employees
Shanghai Junshi Biosciences had 2,670 employees as of June 30, 2025. The number of employees increased by 92 or 3.57% since the number was reported on December 31, 2024.
Employees
2,670
Change
92
Growth
3.57%
Revenue / Employee
$135,289
Profits / Employee
-$51,754
Market Cap
4.60B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 2,670 | 92 | 3.57% | 2,670 | 0 |
| Dec 31, 2024 | 2,578 | -383 | -12.93% | 2,578 | 0 |
| Dec 31, 2022 | 2,961 | 156 | 5.56% | 2,961 | 0 |
| Dec 31, 2021 | 2,805 | 352 | 14.35% | 2,805 | 0 |
| Dec 31, 2020 | 2,453 | 1,067 | 76.98% | 2,453 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
Shanghai Junshi Biosciences News
- 2 months ago - Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis - GlobeNewsWire
- 2 months ago - Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC - GlobeNewsWire
- 4 months ago - Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients - GlobeNewsWire
- 5 months ago - Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints - GlobeNewsWire
- 6 months ago - TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer - GlobeNewsWire
- 6 months ago - Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates - GlobeNewsWire